Quality Measurement in Cancer Care: A Review and Endorsement of High-Impact Measures and Concepts

View More View Less
  • a Duke Cancer Institute, Durham, North Carolina;
  • b National Comprehensive Cancer Network, Plymouth Meeting, Pennsylvania;
  • c The National Patient Advocate Foundation, Washington, DC;
  • d Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois;
  • e Roswell Park Comprehensive Cancer Center, Buffalo, New York;
  • f Flatiron Health, New York, New York;
  • g ADVI, Washington, DC;
  • h Mayo Clinic Cancer Center, Rochester, Minnesota;
  • i Memorial Sloan Kettering Cancer Center, New York, New York; and
  • j The University of Texas MD Anderson Cancer Center, Houston, Texas.
Restricted access

Although oncology care has evolved, outcome assessment remains a key challenge. Outcome measurement requires identification and adoption of a succinct list of metrics indicative of high-quality cancer care for use within and across healthcare systems. NCCN established an advisory committee, the NCCN Quality and Outcomes Committee, consisting of provider experts from NCCN Member Institutions and other stakeholders, including payers and patient advocacy, community oncology, and health information technology representatives, to review the existing quality landscape and identify contemporary, relevant cancer quality and outcomes measures by reevaluating validated measures for endorsement and proposing new measure concepts to fill crucial gaps. This manuscript reports on 22 measures and concepts; 15 that align with existing measures and 7 that are new.

Submitted September 19, 2019; accepted for publication January 10, 2020.

Disclosures: Dr. D’Amico has disclosed that he is a consultant for Scanlan. Dr. Benson has disclosed that he is a scientific advisor for Envision, Merck, Guardantt, Dava Onc, Bayer, Bristol-Myers Squibb, LSK, Association for Value-Based Cancer Care, Threabionic, Terumo, Lexicon, and Incyte. Drs. Green and Meropol have disclosed that they are employees of Flatiron Health, Inc., an independent subsidiary of the Roche Group, and have equity interests in Roche. Dr. Kolodziej has disclosed that he hold stock in CVS. Dr. Kumar has disclosed that he is a scientific advisor for Adaptive Technology and Oncopeptides. The remaining authors have disclosed that they have no financial interests, arrangements, or affiliations with the manufacturers of any products discussed in this article or their competitors.

Correspondence: Lindsey A.M. Bandini, MPH, National Comprehensive Cancer Network, 3025 Chemical Road, Suite 100, Plymouth Meeting, PA 19462. Email: bandini@nccn.org
  • 1.

    Winchester DP. The assurance of quality care for the cancer patient. Cancer 1990;65(3 Suppl):776779.

  • 2.

    Ayanian JZ, Markel H. Donabedian’s lasting framework for health care quality. N Engl J Med 2016;375:205207.

  • 3.

    Rosati RJ. The history of quality measurement in home health care. Clin Geriatr Med 2009;25:121134.

  • 4.

    Department of Health and Human Services. Updates to the Quality Payment Program. Fed Regist 2019;84:40482–41289. Section III.K. Available at: https://www.govinfo.gov/content/pkg/FR-2019-08-14/pdf/2019-16041.pdf. Accessed November 1, 2019.

  • 5.

    Oncology Care First Model: informal request for information. Available at: https://innovation.cms.gov/Files/x/ocf-informalrfi.pdf. Accessed November 13, 2019.

  • 6.

    Miniemyer P. Blues plans to launch high-performance network nationwide in 2021. FierceHealthcare.com. Available at: https://www.fiercehealthcare.com/payer/blues-plans-to-launch-high-performance-network-nationwide-2021. Accessed November 13, 2019.

  • 7.

    U.S. Department of Health and Human Services. HHS Quality Summit (QS) Fact Sheet. Available at: https://www.hhs.gov/about/news/2019/07/09/hhs-quality-summit-fact-sheet.html. Accessed November 13, 2019.

  • 8.

    Centers for Medicare & Medicaid Services. Trump Administration’s Patients Over Paperwork delivers for doctors. Available at: https://www.cms.gov/newsroom/press-releases/trump-administrations-patients-over-paperwork-delivers-doctors. Accessed December 1, 2019.

  • 9.

    American Cancer Society. Cancer Facts & Figures 2015. Available at: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2015.html. Accessed October 3, 2019.

  • 10.

    American College of Surgeons. CoC Quality Care Measures. Available at: https://www.facs.org/quality-programs/cancer/ncdb/qualitymeasures. Accessed December 1, 2019

  • 11.

    American Society of Clinical Oncology. Don’t perform surveillance testing (biomarkers) or imaging (PET, CT, and radionuclide bone scans) for asymptomatic individuals who have been treated for breast cancer with curative intent. ChoosingWisely.org. Available at: https://www.choosingwisely.org/clinician-lists/american-society-clinical-oncology-surveillance-testing-imaging-for-breast-cancer/. Accessed December 1, 2019.

  • 12.

    ASCO QOPI. QOPI 2019 Reporting Tracks. Available at: https://practice.asco.org/sites/default/files/drupalfiles/QOPI-2019-Round-1-Reporting-Tracks-Public-Posting.pdf. Accessed November 1, 2019.

  • 13.

    Quality ID #455 (NQF 0213): percentage of patients who died from cancer admitted to the intensive care unit (ICU) in the last 30 days of life. Available at: https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2019_Measure_455_MIPSCQM.pdf. Accessed December 1, 2019.

  • 14.

    Department of Health and Human Services. CY 2020 Quality Reporting Requirements for Specific Providers. Fed Regist 2019;84:42044–42701. Section VIII. Available at: https://www.govinfo.gov/content/pkg/FR-2019-08-16/pdf/2019-16762.pdf. Accessed November 1, 2019.

  • 15.

    Proportion of patients who died of cancer admitted to the ICU in the last 30 days of life. National Quality Forum. National Quality Forum Endorsed Measures Database Website. Available at: http://www.qualityforum.org/QPS/. Accessed December 1, 2019.

  • 16.

    Quality ID #226 (NQF 0028): preventive care and screening: tobacco use: screening and cessation intervention. Available at: https://qpp.cms.gov/docs/QPP_quality_measure_specifications/Claims-Registry-Measures/2019_Measure_226_MedicarePartBClaims.pdf. Accessed December 1, 2019.

  • 17.

    National Quality Forum. Preventive care and screening: tobacco use: screening and cessation intervention. Available at: http://www.qualityforum.org/QPS/0028. Accessed December 1, 2019

  • 18.

    Quality ID #453 (NQF 0210): percentage of patients who died of cancer receiving chemotherapy in the last 14 days of life. Available at: https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2019_Measure_453_MIPSCQM.pdf. Accessed December 8, 2019.

  • 19.

    National Quality Forum. Proportion of patients who died of cancer receiving chemotherapy in the last 14 days of life. Available at: http://www.qualityforum.org/QPS/0210. Accessed December 1, 2019.

  • 20.

    American College of Surgeons, Commission on Cancer. Oncology Medical Home Accreditation Program Standards Manual. Available at: https://www.facs.org/∼/media/files/quality%20programs/cancer/coc/omh%20manual.ashx. Accessed November 15, 2019.

  • 21.

    National Quality Forum. Oncology: cancer stage documented. Available at: http://www.qualityforum.org/QPS/0386. Accessed December 1, 2019.

  • 22.

    National Quality Forum. Proportion dying from cancer in an acute care setting. Available at: http://www.qualityforum.org/QPS/0214. Accessed December 1, 2019.

  • 23.

    National Quality Forum. Proportion of patients who died of cancer not admitted to hospice. Available at: http://www.qualityforum.org/QPS/0215. Accessed December 1, 2019

  • 24.

    Oncology Care Model. OCM performance-based payment methodology, Version 3.2. Available at: https://innovation.cms.gov/Files/x/ocm-cancercodelists.pdf. Accessed December 1, 2019.

  • 25.

    National Quality Forum. Prostate cancer: combination androgen deprivation therapy for high risk or very high risk prostate cancer. Available at: http://www.qualityforum.org/QPS/0390. Accessed December 1, 2019

  • 26.

    Localized prostate cancer: urinary incontinence. Centers for Medicare & Medicaid Services Measures Inventory Tool. Available at: https://cmit.cms.gov/CMIT_public/ViewMeasure?MeasureId=5656. Accessed December 3, 2019.

  • 27.

    Localized prostate cancer: vitality. Centers for Medicare & Medicaid Services Measures Inventory Tool. Available at: https://cmit.cms.gov/CMIT_public/ViewMeasure?MeasureId=5657. Accessed December 3, 2019.

  • 28.

    National Quality Forum. History of Prostate Cancer - Cancer Surveillance. Available at: http://www.qualityforum.org/QPS/0625. Accessed December 1, 2019.

  • 29.

    McGale P, Taylor C, Correa C, . Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 2014;383:21272135.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Gradishar WJ, Anderson BO, Abraham J, . NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 3.2019. Accessed November 27, 2019. For the most recent version, visit NCCN.org.

  • 31.

    Hahn EE, Hays RD, Kahn KL, . Use of imaging and biomarker tests for posttreatment care of early-stage breast cancer survivors. Cancer 2013;119:43164324.

  • 32.

    Khatcheressian JL, Hurley P, Bantug E, . Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013;31:961965.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 33.

    Seidman A, Hudis C, Pierri MK, . Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20:12151221.

  • 34.

    Moja L, Tagliabue L, Balduzzi S, . Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 2012:CD006243.

  • 35.

    Balduzzi S, Mantarro S, Guarneri V, . Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 2014:CD006242.

  • 36.

    Henry ML, Niu J, Zhang N, . Cardiotoxicity and cardiac monitoring among chemotherapy-treated breast cancer patients. JACC Cardiovasc Imaging 2018;11:10841093.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Benson AB, Venook AP, Al-Hawary MM, . NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 4.2019. Accessed November 27, 2019. For the most recent version, visit NCCN.org.

  • 38.

    Benson AB, Venook AP, Al-Hawary MM, . NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer. Version 4.2019. Accessed November 27, 2019. For the most recent version, visit NCCN.org.

  • 39.

    Survival Rates for Colorectal Cancer. American Cancer Society Website. Available at: https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/survival-rates.html. Accessed November 27, 2019.

  • 40.

    Sargent D, Sobrero A, Grothey A, . Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2009;27:872877.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Kavalieratos D, Corbelli J, Zhang D, . Association between palliative care and patient and caregiver outcomes: a systematic review and meta-analysis. JAMA 2016;316:21042114.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Temel JS, Greer JA, Muzikansky A, . Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;363:733742.

  • 43.

    Sullivan DR, Chan B, Lapidus JA, . Association of early palliative care use with survival and place of death among patients with advanced lung cancer receiving care in the Veterans Health Administration. JAMA Oncol 2019;5:1702.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 44.

    D’Amico AV, Chen MH, Renshaw AA, . Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008;299:289295.

  • 45.

    Denham JW, Steigler A, Lamb DS, . Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 2011;12:451459.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46.

    Jones CU, Hunt D, McGowan DG, . Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011;365:107118.

  • 47.

    Ficarra V, Novara G, Ahlering TE, . Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol 2012;62:418430.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48.

    Chade DC, Eastham J, Graefen M, . Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. Eur Urol 2012;61:961971.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49.

    Shekarriz B, Upadhyay J, Pontes JE. Salvage radical prostatectomy. Urol Clin North Am 2001;28:545553.

  • 50.

    Loeb S, Bruinsma SM, Nicholson J, . Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification. Eur Urol 2015;67:619626.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51.

    Epstein JI, Egevad L, Amin MB, . The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 2016;40:244252.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52.

    Lu-Yao GL, Albertsen PC, Moore DF, . Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer. JAMA Intern Med 2014;174:14601467.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Potosky AL, Haque R, Cassidy-Bushrow AE, . Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer. J Clin Oncol 2014;32:13241330.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    American College of Surgeons, Commission on Cancer. Cancer Program Standards: Ensuring Patient-Centered Care. Available at: https://www.facs.org/-/media/files/quality-programs/cancer/coc/2016-coc-standards-manual_interactive-pdf.ashx. Accessed December 1, 2019.

  • 55.

    Abernethy AP, Herndon JE, Wheeler JL, . Poor documentation prevents adequate assessment of quality metrics in colorectal cancer. J Oncol Pract 2009;5:167174.

  • 56.

    Lara PN Jr, Higdon R, Lim N, . Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol 2001;19:17281733.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57.

    Secretan B, Straif K, Baan R, . A review of human carcinogens—part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol 2009;10:10331034.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 58.

    Warren GW, Cummings KM. Tobacco and lung cancer: risks, trends, and outcomes in patients with cancer. Am Soc Clin Oncol Educ Book 2013;33:359364.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 59.

    Gritz ER, Toll BA, Warren GW. Tobacco use in the oncology setting: advancing clinical practice and research. Cancer Epidemiol Biomarkers Prev 2014;23:39.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    Hanna N, Mulshine J, Wollins DS, . Tobacco cessation and control a decade later: American Society of Clinical Oncology policy statement update. J Clin Oncol 2013;31:31473157.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 61.

    Earle CC, Park ER, Lai B, . Identifying potential indicators of the quality of end-of-life cancer care from administrative data. J Clin Oncol 2003;21:11331138.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62.

    Mack JW, Cronin A, Keating NL, . Associations between end-of-life discussion characteristics and care received near death: a prospective cohort study. J Clin Oncol 2012;30:43874395.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 63.

    Institute of Medicine. Dying in America: Improving Quality and Honoring Individual Preferences Near the End of Life. Washington, DC: The National Academies Press, Institute of Medicine; 2015.

  • 64.

    Kraut J, Mooney K, Sweetenham JW, . Implementing an electronic end-of-life chemotherapy utilization measure. J Oncol Pract 2019;15:220223.

  • 65.

    Adelson KB, Meropol NJ, Hamrick J, . Development of a dashboard for end-of-life care at an academic hospital [abstract]. J Clin Oncol 2018;36(Suppl):Abstract 6590.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 66.

    Porter ME, Larsson S, Lee TH. Standardizing patient outcomes measurement. N Engl J Med 2016;374:504506.

  • 67.

    Hassett MJ. Quality improvement in the era of big data. J Clin Oncol 2017;35:31783180.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 2527 2527 235
PDF Downloads 713 713 43
EPUB Downloads 0 0 0